Testosterone (Aveed, Depo-testosterone, Jatenzo) — 2026 Medicare Part D coverage
testosterone — sold as Aveed, Depo-testosterone, Jatenzo, Kyzatrex, Xyosted: 22 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover testosterone?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| testosterone enanthate 200 MG/ML Injectable Solution generic · RxCUI 835809 | 328 (100%) | 3 | 234 | 0 | 96 |
| testosterone cypionate 100 MG/ML Injectable Solution generic · RxCUI 835829 | 313 (95%) | 2 | 212 | 0 | 0 |
| testosterone cypionate 200 MG/ML Injectable Solution generic · RxCUI 835840 | 312 (95%) | 2 | 211 | 0 | 0 |
| testosterone 1 % (25 MG / 2.5 GM) Transdermal Gel generic · RxCUI 1597123 | 311 (95%) | 4 | 280 | 0 | 264 |
| testosterone 1 % (50 MG / 5 GM) Transdermal Gel generic · RxCUI 1597129 | 311 (95%) | 4 | 280 | 0 | 263 |
| testosterone cypionate 200 MG in 1 ML Injection generic · RxCUI 2047882 | 309 (94%) | 2 | 213 | 0 | 0 |
| testosterone 1.62 % (20.25 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT generic · RxCUI 1597076 | 308 (94%) | 4 | 277 | 0 | 250 |
| testosterone 1 % (12.5 MG/ACTUAT) Transdermal Gel Pump, 60 ACTUAT generic · RxCUI 1596780 | 306 (93%) | 4 | 276 | 0 | 257 |
| testosterone 1.62 % (20.25MG / 1.25GM) Transdermal Gel generic · RxCUI 1597120 | 133 (41%) | 4 | 113 | 0 | 94 |
| testosterone 1.62 % (40.5MG / 2.5GM) Transdermal Gel generic · RxCUI 1597126 | 133 (41%) | 4 | 113 | 0 | 93 |
| testosterone 2 % (30 MG/ACTUAT) Topical Solution, 60 ACTUAT generic · RxCUI 1599949 | 107 (33%) | 4 | 92 | 0 | 91 |
| Depo-Testosterone 100 MG/ML Injectable Solution brand · RxCUI 835831 | 106 (32%) | 3 | 89 | 0 | 0 |
| Depo-Testosterone 200 MG/ML Injectable Solution brand · RxCUI 835842 | 105 (32%) | 3 | 88 | 0 | 0 |
| XYOSTED 100 MG in 0.5 ML Auto-Injector brand · RxCUI 2099686 | 5 (2%) | 3 | 5 | 0 | 4 |
| XYOSTED 50 MG in 0.5 ML Auto-Injector brand · RxCUI 2099691 | 5 (2%) | 3 | 5 | 0 | 4 |
| XYOSTED 75 MG in 0.5 ML Auto-Injector brand · RxCUI 2099697 | 5 (2%) | 3 | 5 | 0 | 4 |
| Aveed 750 MG in 3 ML Injection brand · RxCUI 1490667 | 1 (0%) | 4 | 1 | 0 | 0 |
| JATENZO 158 MG Oral Capsule brand · RxCUI 2201640 | 1 (0%) | 4 | 1 | 0 | 0 |
| JATENZO 198 MG Oral Capsule brand · RxCUI 2201642 | 1 (0%) | 4 | 1 | 0 | 0 |
| JATENZO 237 MG Oral Capsule brand · RxCUI 2121776 | 1 (0%) | 5 | 1 | 0 | 0 |
| KYZATREX 150 MG Oral Capsule brand · RxCUI 2609607 | 1 (0%) | 2 | 1 | 0 | 1 |
| KYZATREX 200 MG Oral Capsule brand · RxCUI 2609611 | 1 (0%) | 2 | 1 | 0 | 1 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.